Testing four medicines in children and teens with hard-to-treat tumors
Treatments studied
Part of Cancer, Digestive system clinical trials.
This early-phase trial studies how safe and effective a combination of four medicines is for children and teens with certain solid tumors that have come back or cannot be controlled with standard treatment. It may help by improving tumor control, while also carefully tracking side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be under age 30 when you start the study
- Have a biopsy-accessible solid tumor that is not responding to standard treatment (or has come back)
- Have tumors that doctors can measure or assess and that are reachable by biopsy
- Be able to meet general health/lab levels (blood counts, kidney, liver, and heart function)
- Not be pregnant or breastfeeding, and use birth control during the study and for 5 months after the last dose
- Be fully recovered from recent treatments (timing rules for chemo, immunotherapy, radiation, and other therapies)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a treatment plan that uses results from genetic testing of your tumor to choose the best targeted therapy. It may help people whose cancer has come back or does not respond to standard treatment by matching treatment to specific tumor changes.
This study collects and studies tissue or bone marrow samples from certain childhood tumors. The goal is to learn what’s going on inside the cancer (using molecular testing) to better understand the disease and how it may respond to treatment.
This trial tests a combination of four drugs (liposomal irinotecan, vincristine, temozolomide, and anlotinib) for children and teens whose solid tumors have come back or not responded to treatment. The goal is to see if this combination can shrink or control the tumor.
This trial tests whether a cancer immunotherapy medicine (atezolizumab) given together with chemotherapy can shrink or control solid tumors that have come back or did not respond to prior treatment. It focuses on children and young adults, including a special subgroup for rhabdomyosarcoma.
This trial tests a new combination of three chemotherapy drugs (eribulin, irinotecan, and temozolomide) for children and young adults whose solid tumors have come back or not responded to standard treatment. The goal is to see if this combination is safe and effective.
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.